Showing results (141-150 of 155) with videos related to

Sort By:
Pageof 16
Oncotarget|May 7, 2014
Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinomaMing-Huang Chen, Kun-Chun Chiang, Chi-Tung Cheng, et al.
Journal of Hepato-Biliary-Pancreatic Sciences|February 19, 2022
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorinTai-Jan Chiu, Shih-Hung Yang, Sz-Chi Chiu, et al.
Gut|December 18, 2021
Reversal of pancreatic desmoplasia by a tumour stroma-targeted nitric oxide nanogel overcomes TRAIL resistance in pancreatic tumoursHsi-Chien Huang, Yun-Chieh Sung, Chung-Pin Li, et al.
Frontiers in Oncology|July 11, 2022
Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter StudyYung-Yeh Su, Nai-Jung Chiang, Chung-Pin Li, et al.
Cancers|February 15, 2022
Strategic Decoy Peptides Interfere with MSI1/AGO2 Interaction to Elicit Tumor Suppression EffectsYi-Ping Yang, Andy Chi-Lung Lee, Liang-Ting Lin, et al.
Cancers|February 25, 2023
Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic CancerYung-Yeh Su, Nai-Jung Chiang, Yi-Hsin Yang, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 1, 2025
Carbon ion therapy for pancreatic cancer with risk-adapted dose escalation: initial clinical experienceI-Chun Lai, Yu-Mei Kang, Yuan-Hung Wu, et al.
Cancers|January 11, 2022
Microsatellite Instability, Epstein-Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric CancerHung-Yuan Yu, Chung-Pin Li, Yi-Hsiang Huang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 29, 2025
Stroma-targeted gene delivery for efficient immunogene therapy against pancreatic cancerHsi-Chien Huang, Yi-Ju Chen, Mei-Wei Lin, et al.
JAMA Oncology|September 23, 2016
Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh ScoreAndrew X Zhu, Ari David Baron, Peter Malfertheiner, et al.
Pageof 16